Role of lymph node dissection at the time of open or minimally invasive nephroureterectomy

被引:8
作者
McIntosh, Andrew G. [1 ]
Umbreit, Eric C. [1 ]
Wood, Christopher G. [1 ]
Matin, Surena F. [1 ]
Karam, Jose A. [2 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Urol, 1515 Holcombe Blvd,Unit 1373, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Urol & Translat Mol Pathol, Houston, TX 77030 USA
关键词
Lymph node dissection (LND); nephroureterectomy; urothelial carcinoma (UC); UPPER URINARY-TRACT; TRANSITIONAL-CELL CARCINOMA; TEMPLATE-BASED LYMPHADENECTOMY; UROTHELIAL CARCINOMA; RADICAL NEPHROURETERECTOMY; RENAL PELVIS; MINIMUM NUMBER; BLADDER; IMPACT; MANAGEMENT;
D O I
10.21037/tau.2019.11.34
中图分类号
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
摘要
Unlike urothelial carcinoma of the bladder, there is no guideline-based consensus on whether a lymph node dissection (LNI)) should be performed at the time of radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC). Variable lymphatic drainage based on primary tumor location, lack of prospective trials, and difficulties in developing a risk-adapted approach to LND for UTUC are all challenges to the development of an established approach. The UTUC literature consists of an evidence pool that has historically been limited to single-institution series with heterogenous inclusion criteria for LND and variable LND templates. Areas of controversy exist regarding migration to the great vessel LN beds for mid and distal tumors. A lack of template standardization limits the interpretation of studies relative to one another and a lack of uniformity in reporting templates may lead to inaccuracies in the estimation of lymph node metastasis landing sites. Most clinicians agree that there is a staging benefit to LND for UTUC. Although the data is somewhat heterogenous, it demonstrates a prognostic and staging benefit to LND in higher stages of UTUC. Unlike the staging benefits provided by LND for UTUC, the therapeutic benefits are not as clearly established. Several studies have evaluated differences in cancer-specific survival (CSS) and demonstrated LNI) to be an independent predictor of CSS when compared to patients not undergoing LND. However, this finding is not consistent across all studies and the literature is again limited by inclusion heterogeneity and inconsistent or lack or template-based resections. LND for UTUC at the time of RNU is a safe and feasible procedure that seems to especially benefit patients with muscle-invasive or locally advanced disease. Prospective, randomized studies with strict inclusion criteria and defined anatomic templates are needed to definitely characterize the role of LND for UTUC.
引用
收藏
页码:2233 / 2245
页数:13
相关论文
共 51 条
  • [1] Nodal involvement in bladder cancer cases treated with radical cystectomy: Incidence and prognosis
    Abdel-Latif, M
    Abol-Enein, H
    El-Baz, M
    Ghoneim, MA
    [J]. JOURNAL OF UROLOGY, 2004, 172 (01) : 85 - 89
  • [2] Role of lymph node dissection in the treatment of urothelial carcinoma of the upper urinary tract: Multi-institutional relapse analysis and immunohistochemical re-evaluation of negative lymph nodes
    Abe, T.
    Shinohara, N.
    Muranaka, M.
    Sazawa, A.
    Maruyama, S.
    Osawa, T.
    Harabayashi, T.
    Kubota, K.
    Matsuno, Y.
    Shibata, T.
    Toyada, Y.
    Shinno, Y.
    Minami, K.
    Sakashita, S.
    Kumagai, A.
    Takada, N.
    Togashi, M.
    Sano, H.
    Mori, T.
    Nonomura, K.
    [J]. EJSO, 2010, 36 (11): : 1085 - 1091
  • [3] Troubling Outcomes From Population-level Analysis of Surgery for Upper Tract Urothelial Carcinoma
    Abouassaly, Robert
    Alibhai, Shabbir M. H.
    Shah, Nasir
    Timilshina, Narhari
    Fleshner, Neil
    Finelli, Antonio
    [J]. UROLOGY, 2010, 76 (04) : 895 - 901
  • [4] AKAZA H, 1987, CANCER-AM CANCER SOC, V59, P1369, DOI 10.1002/1097-0142(19870401)59:7<1369::AID-CNCR2820590724>3.0.CO
  • [5] 2-A
  • [6] Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: value of lymph-node density
    Bolenz, Christian
    Shariat, Shahrokh F.
    Fernandez, Mario I.
    Margulis, Vitaly
    Lotan, Yair
    Karakiewicz, Pierre
    Remzi, Mesut
    Kikuchi, Eiji
    Zigeuner, Richard
    Weizer, Alon
    Montorsi, Francesco
    Bensalah, Karim
    Wood, Christopher G.
    Roscigno, Marco
    Langner, Cord
    Koppie, Theresa M.
    Raman, Jay D.
    Mikami, Shuji
    Michel, Maurice Stephan
    Stroebel, Philipp
    [J]. BJU INTERNATIONAL, 2009, 103 (03) : 302 - 306
  • [7] Retroperitoneal lymph node dissection (RPLD) in conjunction with nephroureterectomy in the treatment of infiltrative transitional cell carcinoma (TCC) of the upper urinary tract: Impact on survival
    Brausi, Maurizio A.
    Gavioli, Mirko
    De Luca, Giuseppe
    Verrini, Giorgio
    Peracchia, GianCarlo
    Simonini, GianLuca
    Viola, Massimo
    [J]. EUROPEAN UROLOGY, 2007, 52 (05) : 1414 - 1420
  • [8] No overt influence of lymphadenectomy on cancer-specific survival in organ-confined versus locally advanced upper urinary tract urothelial carcinoma undergoing radical nephroureterectomy: a retrospective international, multi-institutional study
    Burger, Maximilian
    Shariat, Shahrokh F.
    Fritsche, Hans-Martin
    Ignacio Martinez-Salamanca, Juan
    Matsumoto, Kazumasa
    Chromecki, Thomas F.
    Ficarra, Vincenzo
    Kassouf, Wassim
    Seitz, Christian
    Pycha, Armin
    Tritschler, Stefan
    Walton, Thomas J.
    Novara, Giacomo
    [J]. WORLD JOURNAL OF UROLOGY, 2011, 29 (04) : 465 - 472
  • [9] Comparing lymphadenectomy during radical nephroureterectomy: Open versus laparoscopic
    Busby, J. Erik
    Brown, Gordon A.
    Matin, Surena F.
    [J]. UROLOGY, 2008, 71 (03) : 413 - 416
  • [10] Anatomical templates of lymph node dissection for upper tract urothelial carcinoma: a systematic review of the literature
    Campi, Riccardo
    Minervini, Andrea
    Mari, Andrea
    Hatzichristodoulou, Georgios
    Sessa, Francesco
    Lapini, Albero
    Sessa, Maurizio
    Gschwend, Jurgen Erich
    Serni, Sergio
    Roscigno, Marco
    Carini, Marco
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (03) : 235 - 246